Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Aug 01,2022
Medicilon has been listed in the 2021 "Top 20 CXO (including CDMO) Enterprises in China" for 4 consecutive years
On July 12, the 2021 "Top 20 CXO (including CDMO) Enterprise in China" selected by Menet was officially released, which once again demonstrated the professionalism and influence of a strong enterprises in China's pharmaceutical industries.
More
Medicilon has been listed in the 2021 "Top 20 CXO (including CDMO) Enterprises in China" for 4 consecutive years
Jul 11,2022
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
On June 28, 2022, Shanghai Medicilon Inc. (Medicilon) and Shanghai BravoBio Co. Ltd. (BravoBio) signed a strategic collaboration agreement online to officially become the collaboration partner.
More
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
Jul 11,2022
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
On June 24, 2022, Shanghai Medicilon Inc. (Medicilon) and ACON Pharmaceuticals Inc. (ACON) reached a strategic collaboration.
More
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
Jul 11,2022
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
On June 28, 2022, Medicilon and ZY Therapeutics signed a strategic collaboration on preclinical IND application services to jointly promote development of gene therapy drugs.
More
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
Jul 04,2022
Medicilon and Suzhou Langrui have reached a strategic collaboration
On June 19, 2022, Shanghai Medicilon Inc. and Suzhou Langrui Biomedical Co., Ltd. signed a strategic collaboration agreement on innovative drug research and development services.
More
Medicilon and Suzhou Langrui have reached a strategic collaboration
Jul 04,2022
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
On June 10, 2022, Bio-Thera Solutions, Ltd. (Bio-Thera) announced that BAT2022 for injection has obtained a clinical trial approval.
More
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
Jul 04,2022
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug
On June 23, 2022, Shanghai Medicilon Inc.,Welman Pharmaceutical and Shenzhen Mingyu New Drug Research and Development Co., Ltd. signed a strategic collaboration on preclinical IND application services.
More
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug
Jul 04,2022
Medicilon and Xiling Lab formed a strategic partnership
On June 17, 2022, Shanghai Medicilon Inc. and Xiling Lab signed a strategic collaboration agreement on innovative drug research and development services in Tianfu Life Science Park.
More
Medicilon and Xiling Lab formed a strategic partnership
Jul 01,2022
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
On June 28, 2022, Shanghai Medicilon Inc. ("Medicilon”) and Shanghai BravoBio Co., Ltd ("BravoBio”) held an online ceremony for signing the Strategic Cooperation Agreement, which marks the two companies have officially become cooperative partners.
More
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
Jun 17,2022
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
​Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Jingxuan Zhang as the Vice President of the Preclinical Toxicology Research.
More
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
Jun 10,2022
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
Shanghai Medicilon Inc. (Medicilon) provided CC312 with a comprehensive preclinical study (including pharmacokinetics and safety evaluation) that complied with GLP specifications with compliant, efficient and high-quality services.
More
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
May 18,2022
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
Recently, Shanghai Medicilon Inc. (Medicilon, stock code: 688202.SH) announced the appointment of Dr. Jing Deng as the Vice President of the Pharmacology and Biology Department.
More
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->